Market Research Blog – Page 14555 – New Product Development

Phospho-specific Antibodies Market Revenue Growth Predicted by 2028

Phospho-specific antibodies are the antibodies which are popularly searched antibodies across the globe. The research on these products starts recently. The process powers over the Post Translational Modification which participates in cell signalling pathway regulation guiding a wide range of cellular processes by 2 ways: It helps to set up newly specific protein-binding sites & formed some functional protein compounds or it helps to generate conformational changes at specific residues by phosphorylation process, leads to the altered enzymatic activity. Phospho-specific antibodies are used in various validation methods, such as in western blotting, Flow cytometry, Immunohistochemistry among other procedures. The ongoing researches on phospho-specific antibodies leads to the diagnosis of many human diseases such as cancer, diabetes, endocrine disease, among other chronic disease. It drives the Phospho-specific antibodies market. Also, phospho-specific antibody for tyrosine, which specifically binds to phosphorylated tyrosine residues, is a valuable tool for analyzing tyrosine kinase activity in high-throughput drug discovery research.

Phospho-specific Antibodies Market: Drivers and Restraints

Rise in the incidence & prevalence of human diseases such as diabetes, cardiovascular disease, cancer, inflammation, neurodegenerative diseases, is expected to the growth of the Phospho-specific Antibodies Market because these antibodies helps in protein therapeutics. Also, Phospho-specific Antibodies holds an important place in drug discovery and development activities, by various biopharmaceutical companies, leading to new and better drug introductions will help in rapid growth of the demand the product over the forecast period. All companies are focusing on developing high-specificity phospho-specific antibodies across the globe which attracts the focus of all the end users of the product. The introduction of herbal treatment for human diseases such as diabetes and cancer increase the competition for the Phospho-specific Antibodies product which restraints the Phospho-specific Antibodies market.

Phospho-specific Antibodies Market: Overview

The global concerned market is experiencing a fast growth due to increasing awareness among end user segment regarding protein therapeutics. TrkA (Phospho-Tyr791) Antibodies dominate the concerned market in product segment criteria. The concerned market is driven by the increase in the incidence & prevalence rate of chronic diseases. The Research centers, & the diagnostic Laboratories segment generates highest revenue share in the end users segment owing to anticipated to register highest growth rate over the forecast period. The key players in the concerned market are focusing on product development & geographical expansion to increase the business footprints.

Phospho-specific Antibodies Market: Region-Wise Overview

The global Phospho-specific Antibodies market is segmented into the following regions – North America, Latin America, Asia-Pacific, Europe, & the Middle East & Africa. North America dominates the global Phospho-specific Antibodies market. This is due to high focus of the research institutes on drug discovery and development in this region. Asia Pacific is the second largest market. This is due to elevated government support and investment in Research & Development about Phospho-specific Antibodies products in this region, & rapidly growing healthcare companies in this region. Europe Phospho-specific Antibodies market is anticipated to grow substantially due to the provision of the discounts on the product in the region which drives the concerned market. Elevation in the Latin America and the Middle East and Africa is growing steadily.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-7840

Phospho-specific Antibodies Market: Key Participants

Some of the key players in the Phospho-specific Antibodies market are ThermoFisher Scientific, Genscript, BioRad Laboratories, Innovagen AB, Davids Biotechnologie GmbH, AnaSpec Inc, Neo Scientific, Rockland Immunichemicals Inc, Creative-Biolabs, Creative Diagnostics, Bethyl Laboratories, Inc. among other companies.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also includes projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain

The regional analysis includes:

North America (U.S., Canada)
Latin America (Mexico, Brazil)
Western Europe (Germany, Italy, France, U.K, Spain)
Eastern Europe (Poland, Russia)
Asia-Pacific Excluding China & Japan (India, ASEAN, Australia & New Zealand)
China
Japan
The Middle East & Africa (GCC Countries, S. Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Request a Complete TOC of this Report with figures:
https://www.futuremarketinsights.com/toc/rep-gb-7840

About FMI:
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:
Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Early-Stage Lung Cancer Diagnostics Therapy Market Insights and Forecast by 2028

Early-Stage Lung Cancer Diagnostics Therapy Market Overview

Cancer is the second most active disease in the world currently by the no. of deaths it is responsible for. Today’s complex time has issued an alarming situation for the consumers as well as the manufacturers to limit the cases with early diagnosis on every term. Early-stage lung cancer diagnostics therapy is performed to diagnose the presence of cancer cells in lungs with immediate care offered. Cancer was a leading cause of death worldwide. According to the National Cancer Institute at the National Institutes of Health, around 8.2 million cancer deaths and 14 million new cases were registered in 2012. The need for a well-organized early-stage lung cancer diagnostics therapy in is due to the fact that only 18% of the lung cancer cases get recognized while the remaining undiagnosed cancer cases progress into more hostile forms of cancer cells, which reduces the survival rate to only few percent’s in patients that are diagnosed with late-stage lung cancer.

Early-Stage Lung Cancer Diagnostics Therapy Market: Drivers and Restraints

Often the fact is ignored that the patients are prime responsible in order to run a business as crucial as early-stage lung cancer diagnostics therapy. Where the first push to enter an early-stage lung cancer diagnostics therapy is dependent on the subject (patient) as the call for early detection by identifying few symptoms is his/her take. Also due to lack of resources and a rising middle class population the diagnosis can be delayed by months or even years in cases and few companies and government initiatives are taking advantage to clear that cloud. Early-stage lung cancer diagnostics therapy is the first line of treatment which starts from diagnosis of present cancer cells, it would significantly decrease global cancer mortality by diagnosing at a remediable stage. Early-stage lung cancer diagnostics therapy involves the advancement of lung cancer-specific biomarkers which is also termed to be an early-stage lung cancer diagnostics therapy is one of the key factors for the development of the early-stage lung cancer diagnostics therapy market over the forecast period. These early-stage lung cancer diagnostics therapy ease the modified treatment method of lung malignancies. The market for early-stage lung cancer diagnostics therapy is restricted regarding their use, low healthcare expenditure in developing regions, costs considerations, etc.

Early-Stage Lung Cancer Diagnostics Therapy Market: Overview

The global market early-stage lung cancer diagnostics therapy is consolidated with several players operating in the global space. Combined approaches of using early-stage lung cancer diagnostics therapy with better technological advancements to omit the undue problems while performing the diagnosis procedure. Some of the established companies for early-stage lung cancer diagnostics therapy are Abbott Laboratories, Danaher Corporation, Thermo Fischer Scientific, Inc. And Roche Holding AG.

Early-Stage Lung Cancer Diagnostics Therapy Market: Regional Wise Outlook

Geographically, the Early-Stage Lung Cancer Diagnostics Therapy Market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific Excluding China and Japan, Japan, China, Middle East and Africa. The North America account for a significant market share owing to extensive use of medication and cancer programs being initiated. Additionally, the fastest uptake of new methods in the US drives the early-stage lung cancer diagnostics therapy market. Western Europe is the second largest market in the world due to high income and healthcare penetration. Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector during the forecast period for early-stage lung cancer diagnostics therapy market. Gulf nations such as Saudi Arabia and the UAE are projected to drive the Middle East & African market, moderate growth is expected owing to poor economic and healthcare development. China is expected to take a progressive step in the market for global early-stage lung cancer diagnostics therapy market throughout the forecast period due to its reformed healthcare policies and public initiatives to cut down the prevalence rate.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-7843

Demographic change in respective countries show different landscape for early-stage lung cancer diagnostics therapy, with the volume of such procedures is more in developed countries as compare to countries in Latin America and Africa.

Early-Stage Lung Cancer Diagnostics Therapy Market: Key Players

Examples of some of the major players in the global Early-Stage Lung Cancer Diagnostics Therapy Market are Abbott Laboratories, Danaher Corporation, Thermo Fischer Scientific, Inc., QIAGEN N.V., Illumina, Inc., Quest Diagnostics Incorporated, NanoString Technologies. Inc, NeoGenomics Laboratories, Inc., Myriad Genetics, Inc. and Roche Holding AG. are some of the key players operating in this market. Technological advancements in biomarkers is the major trend emerging in the global early-stage lung cancer diagnostics therapy market.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

The report covers exhaustive analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain

Regional analysis includes

North America (U.S., Canada)
Latin America (Mexico, Brazil)
Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
Asia Pacific Excluding Japan and China (India, Australia & New Zealand, ASEAN)
Japan
China
Middle East and Africa (GCC, S. Africa, Rest Of MEA)

Report Highlights:

Detailed overview of parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint.

For critical insights, request for PDF Brochure https://www.futuremarketinsights.com/reports/brochure/rep-gb-7843

Microfluidic Modulation Spectroscopy Market Set for Rapid Growth by 2028

Microfluidic Modulation Spectroscopy Market Overview

Microfluidic Modulation Spectroscopy: Market Insights

Microfluidic modulation spectroscopy is an emerging technique of spectroscopy for analysing the secondary structure of the protein. The company named RedShift BioAnalytics launched a product named AQS3 which uses the patented technique of microfluidic modulation spectroscopy. This technique uses mid-infrared laser spectroscopy in microfluidics environment and uses advanced signal processing to measure the secondary structure of proteins. This type of innovative spectroscopy is implemented to measure and quantify the protein along with its stability, similarity, structure and aggregate formation. This technique can be implemented on a broad variety of conditions and is sensitive and precise. The function of the protein changes by conformational change and this could be an influencing factor in quality control of proteins such as antibodies and enzymes manufacturing companies. Such structural changes can be precisely and sensitively detected by the microfluidic modulation spectroscopy. It also aids researchers to find stable and suitable antibodies. The advancements and innovative product launches in medical and life science in the past years is expanding the understanding of biological systems at the molecular level and generates more opportunities in the microfluidic modulation spectroscopy. Therefore, a constant incremental opportunity for the manufacturing company can be anticipated during the forecast period.

Microfluidic Modulation Spectroscopy: Market Dynamics

The key factors contributing to the growth of the global microfluidic modulation spectroscopy market include research & developments associated with microfluidic modulation spectroscopy as well as continuous improvement in the technological processes contributes in driving the market. Greater adoption is expected to be noted in pharmaceutical quality control and drug designing techniques over the forecast period. Moreover, the microfluidic modulation spectroscopy finds applications in other fields such as forensic studies, industrial production, immunology and biotechnology industries, etc. and thus is anticipated to lure end users in buying this patented technology. Lack of awareness about the product can be considered as a barrier in the fast growth of microfluidic modulation spectroscopy in the market.

Microfluidic Modulation Spectroscopy: Overview

The concerned market is highly consolidated in nature owing to the fact that it is a patented technology. However, the microfluidic modulation spectroscopy is expected to register fast growth in the spectroscopy market for its application in the medical science over the forecast period. The device is yet to make a mark in developing countries with low resource base owing to the lack of knowledge about the product and absence of distributors. RedShift BioAnalytics, Inc. launched the first microfluidic modulation spectroscopy in April 2018 and is since trying to popularize the product by conducting conferences, providing online detailed product information, arranging trials and explaining the varied and precise functions performed by the device and its advantages over other spectrometers. The company is focusing on increasing its sale team in order to expand the company’s reach and satisfy the demands from end users. For instance, in May 2018 the company expanded its sales team with key hire.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-7841

Microfluidic Modulation Spectroscopy: Region-wise Outlook

On the basis of geography, the global microfluidic modulation spectroscopy market is segmented into seven key regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan, and Middle East & Africa.The North America market for microfluidic modulation spectroscopy market holds the largest revenue share owing to the product availability and high demand by academic institutes as well as biopharmaceutical companies. Europe is Asia Pacific excluding Japan microfluidic modulation spectroscopy market is also wide open for the company to increase its sale and increase its revenue and is anticipated to register a fast growth over the forecast period. The Middle East & Africa microfluidic modulation spectroscopy is expected to witness slow growth owing to the limited healthcare expenditure and low per capita income in the region.

Microfluidic Modulation Spectroscopy: Key Player

The key player present in the global microfluidic modulation spectroscopy market are RedShift BioAnalytics, Inc.

The report covers exhaustive analysis on:

Market Segments
Market Dynamics
Market Size
Current Trends/Issues/Challenges
Competition & Companies involved
Value Chain

The regional analysis includes:

North America (U.S., Canada)
Latin America (Mexico. Brazil)
Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
Eastern Europe (Poland, Russia)
Asia-Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
Japan
The Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

For any queries linked with the report, ask an analyst >> https://www.futuremarketinsights.com/ask-question/rep-gb-7841

Laparoscopic Devices Market is projected to experience significant growth during the next decade

The global laparoscopic devices market is projected to experience significant growth during the next decade (2019 – 2029), on the back of rapid growth in demand for minimally invasive surgery and expanding application potential in colorectal and bariatric surgical procedures. By the end of 2019, global sales of laparoscopic devices accounted for revenues of over US$ 10 Bn. Increasing FDI influx in developing regions coupled with marketing and promotional activities are expected to boost the laparoscopic devices market over the following years, says the report.

Key Takeaways – Laparoscopic Devices Market Study

Steady demand growth is observed for bariatric surgery, in line with the expanding obese population coupled with wide-scale adoption rate of minimally invasive techniques. Sales of laparoscopic devices for bariatric surgery will surpassing that for colorectal surgery towards the end of projection period.
Sales of laparoscopic devices will be higher in North American countries. The availability of skilled surgeons and several advantages of minimally invasive surgery over open surgery are few factors driving the market of laparoscopy devices.
The key players in the laparoscopic devices market are focusing on technologically advanced surgical systems with improved dexterity, ergonomics, and visual enhancements that provide advantages to surgeons and minimize the risk for patients while undergoing laparoscopic procedures.
Increasing consumer base along with modern amenities in the healthcare sector is expected to drive sales of laparoscopic devices in developing regions.

Growing Popularity of Single-incision Laparoscopic Surgery

Single-site incisional surgery is being widely used in laparoscopic procedures and is replacing traditional method of laparoscopic procedures, in which four to five small incisions were made as the entry point for laparoscopic instruments. Some of the key benefits of single-site incision laparoscopic procedure over traditional procedure are low chances of infections, better cosmetic results, quick recovery and less post-operative pain.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-497

According to Journal of the Society of Laparoendoscopic Surgeons (JSLS), women who undergo single-site incision laparoscopic surgery tend to report lesser post-operative pain compared to traditional method laparoscopic surgery. Growing demand for single-incision laparoscopic surgeries would thus drive the growth of laparoscopic devices market.

Adoption of Subscription Commerce Marketing Model

Companies are adopting various marketing model schemes such as subscription commerce to boost the sale of laparoscopic devices. Under this scheme, companies provide medical devices such as laparoscopy devices on pay-per-use basis. Thus, various end use segments can have access to these devices which might otherwise be prohibitively expensive, which in turn is helping manufacturers to expand their market share for laparoscopic devices, globally.

Due to intense competition, manufacturers of laparoscopic devices use innovative pricing strategies to remain at the forefront. Expanding access of laparoscopic devices by educating healthcare professionals through various conferences and training is enabling companies manufacturing these devices to enhance the adoption and equipping healthcare facilities with the necessary tools to provide optimal care to patients.

Interested in More About Report Inclusions?

Laparoscopic Devices Market, a new study from Future Market Insights, opines on the evolution of the laparoscopic devices market from 2014 – 2018 and presents demand projections from 2019 – 2029 on the basis of product type (direct energy system devices, trocars/access device, internal closure devices, laparoscopes, hand access instruments, insufflation devices, and robotic assisted surgical system), therapeutic application (bariatric surgery, colorectal surgery, general surgery, gynecological surgery and urological surgery), and end user (hospitals, ambulatory surgical centers, and clinics) across seven major regions.

Request a Complete TOC of this Report with figures:
https://www.futuremarketinsights.com/toc/rep-gb-497

Liquid Biopsy Market is expected to total US$ 3,637 Million by 2031

As per a recent market survey by ESOMAR-certified consulting firm Future Market Insights (FMI), the global liquid biopsy market is expected to reach a market valuation of US$ 1,026 Mn in 2021.

With the introduction of innovative molecular diagnostic tests and growing demand from biotech and pharmaceutical companies, the market is poised to expand at a stellar 13.49% CAGR, reaching US$ 3,637 Mn by 2031.

Growth of the liquid biopsy market is attributable to rising incidence of cancer across several countries, which is highlighting the pressing need for faster, simpler, and more convenient diagnostic procedures. Liquid biopsy procedures are minimally invasive and cost-effective, which is making them a favorable choice for cancer diagnosis procedures.

Besides this, increasing government-backed initiatives to support cancer research across the U.S., Japan, India and the UK will drive innovation and developments in liquid biopsy services. Also, fast track approval from regulatory bodies for novel procedures will bolster the growth over the coming years.

Additionally, technological advancements such as the incorporation of machine learning and microchip-based liquid biopsy systems will further strengthen growth prospects in the market.

As per the market survey, counties including the U.S., the U.K, and Japan will be at the forefront of innovation and adoption of liquid biopsy services, owing to the presence of leading players and prevalence of numerous high-potential cancer research institutes.

Germany, India, and China will emerge as high growth potential markets, with increasing investments by the government for improving the healthcare infrastructure, which will create attractive opportunities to global biotech players for market expansion.

Key Takeaways from the Liquid Biopsy Market Analysis

Based on markers, circular tumor cells (CTC) are poised to emerge dominant in the forthcoming years.
Blood samples will emerge as the most preferred sample type
In terms of applications, liquid biopsy will be widely preferred for lung cancer diagnosis.
Cancer institutes are expected to remain dominant end users, accounting for over 40% of the total revenue share.
The U.S. will showcase high growth during the forecast period, due to the presence of major liquid biopsy product manufacturers.
The U.K. will emerge as an avenue for product innovations and development, further solidifying growth prospects.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1396

Japan is anticipated to witness upswings in sales, owing to government-led cancer research initiatives.
India is expected to showcase high demand for liquid biopsy products, owing to the increased funding by government and expansion of healthcare infrastructure.

Competitive Landscape

BIOCEPT, INC., Qiagen N.V., Trovagene, Inc, Janssen Global Services, LLC, MDxHealth SA, Natera, Inc, F. Hoffmann-La Roche Ltd, Silicon Biosystems, Pathway Genomics Corporation, and Sysmex Corporation are among top manufacturers of liquid biopsy products, as profiled by FMI. As per the market survey, tier-1 companies are anticipated to account for approximately 20-25% of the total market share.

Strategic collaborations, partnerships, and product innovations are some of the prominent growth strategies applied by leading market players to establish a strong foothold in the liquid biopsy market. For instance:

In June 2021, Biocept Inc., collaborated with Quest Diagnostics, a New Jersey-based clinical laboratory, to offer laboratory services to Quest patients for its Target Selector NGS-based liquid biopsy lung cancer panel.
In February 2021, Menarini Silicon Biosystems, a leading developer of liquid biopsy and single-cell technologies, launched its innovative CellMag product line for staining and detection of rare circulating tumor cells (CTCs).

More Insights into the Liquid Biopsy Market Report

In its latest report, FMI offers an unbiased analysis of the global liquid biopsy market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of marker type (circulating tumor cells (CTC), circulating tumor nucleic acids (cTNA) and exosomes), sample type (blood, urine and other including plasma, saliva and CSF), application type (lung cancer, gastrointestinal cancer, prostate cancer, colorectal cancer, leukemia), end-users (hospitals, cancer institutes, academic institutes, and diagnostic centers) and across seven regions (North America, Latin America, Eastern Europe, Western Europe, Asia Pacific excluding Japan (APEJ), Japan, and Middle East & Africa).

For critical insights, request for PDF Brochure https://www.futuremarketinsights.com/reports/brochure/rep-gb-1396

Dermal Fillers Market is projected to exhibit 2.9% CAGR over 2031

Growing inclination towards non-invasive procedures and increasing efficiency of dermal fillers have been driving the dermal fillers market. Future Market Insights (FMI) in a new study has projected the market to reach US$ 4.04 Bn by the end of 2021. The application of dermal fillers ranges from better aesthetic outcomes to the treatment of forehead augmentation.

The use of dermal fillers is not restricted to facial skin procedures, it also includes various derma aesthetic procedure treatment. Moreover, an increase in the number of non-invasive aesthetic surgeries and an increasing number of aesthetic surgeons are expected to be important factors for surging the demand for dermal fillers.

According to the Plastic Surgery Statistics Report, in 2019, there were around 13,618,735 non-surgical procedures performed by plastic surgeons worldwide.

Additionally, increasing awareness concerning the dermal fillers in emerging countries, the emergence of new products and d new indications are enabling growth. Besides this, the rising ageing population is one of the major factors that is rapidly fuelling the demand for dermal fillers. The rising demand for anti-ageing treatment to effectively diminish the signs of ageing and facial treatment will keep the demand for dermal fillers high.

FMI has projected absorbable dermal fillers to remain most preferred. It is expected to account for over 99% of dermal fillers sold through 2031.

Key Takeaways of Dermal Fillers Market Study

The global dermal fillers market will continue expanding at a steady pace. FMI has projected the market to exhibit 2.8% Y-o-Y growth in 2021
The U.S. is one of the key markets for dermal fillers, accounting for over 89% of North America market in 2021
Demand for dermal fillers is expected to remain significantly high in the U.K. FMI has projected it to exhibit over 5% Y-o-Y growth in 2021
Germany and France are other lucrative markets for dermal fillers in Europe
Dermal fillers sales in Japan are expected to be considerably high. South Korea too will continue exhibiting rising demand for dermal fillers

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-5699

Who is Winning?

The regulatory approval for new products is one of the key factor responsible for enormous competition among market players globally. Some of the leading market players have been focusing on product launches. Besides this mergers & acquisitions and collaboration remain the key trends among market players intending to expand their footprint globally.

For instance, AbbVie Inc., acquired Allergan Aesthetics, the onset of the completion of its acquisition of Irish-domiciled pharmaceutical company in January 2020. Allergan Aesthetics would operate as a new global dedicated business with its research & development function including aesthetic products, botox Cosmetic, the Juvederm collection of dermal fillers, and Coolsculpting body contouring.

Also, Revance Therapeutics signed an exclusive U.S. distribution agreement in January 2020 with Teoxane SA for its innovative Resilient Hyaluronic Acid products like RHA2, RHA3, and RHA4. Hence this agreement would expand the Teoxane’s aesthetic products sales.

In Oct 2020, Sinclair Pharmaceuticals Ltds. signed a strategic distributorship agreement with Tamer Group KSA, intending to expand its aesthetic profile sales footprint in the Middle East and Africa with its exclusive distributor in Saudi Arabia.

More Valuable Insights on Dermal Fillers Market

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each segment from 2014 to 2029. The global dermal fillers market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on dermal fillers market on basis of product type (absorbable, non-absorbable), by ingredient (hyaluronic acid, poly-L-lactic acid, calcium hydroxylapatite, polymethyl methacrylate, and collagen), and distribution channel (retail pharmacies and drug stores, clinic and hospital pharmacies, online pharmacies), across seven major regions.

For any queries linked with the report, ask an analyst >> https://www.futuremarketinsights.com/ask-question/rep-gb-5699

Veterinary Biologics Market is expected to exhibit a CAGR of 7% during the forecast period

Rising trend of pet ownership across the world has increased concerns related to pet health, resulting in rising demand for veterinary biologics. According to the American Pet Products Association (APPA), around 67% of U.S. households own a pet, which is a significant rise of 56% since 1988. Preventive veterinary biologics such as vaccines are most widely used as prophylactic treatment. Increase in usage of prophylactic veterinary biologics is primarily attributed to growing awareness about better pet health management and risk of various diseases such as rabies. Recently, the World Health Organization (WHO) endorsed the use of veterinary biologics such as monoclonal antibodies over blood-derived rabies immunoglobulin. Such endorsements and quest for more safe & effective veterinary biologics have resulted in increased R&D spending.

The global veterinary biologics market is expected to exhibit a CAGR of 7% during the forecast period (2019–2029).

Key Takeaways of Veterinary Biologics Market Study

Owing to rapid adoption of vaccines as a prophylactic treatment for better herd immunity, the segment is expected to be a significant revenue generator.
Growing adoption of monoclonal antibodies for dermal disorder treatment in companion animals is anticipated to contribute to the dominance of the segment during the forecast period.
Rising prevalence of infectious diseases in livestock has boosted the demand for veterinary biologics. Livestock is expected to be a significant revenue generating segment by animal type, during the forecast period.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2288

By distribution channel, the veterinary biologics market is dominated by veterinary clinics in terms of revenue, owing to direct customer contact for bulk orders.
Europe is anticipated to be the most lucrative region in terms of revenue, due to growing adoption of animals for commercial use. East Asia is expected to witness notable growth during the forecast period.

Mergers & Acquisitions Key Strategy of Veterinary Biologic Manufacturers

Manufacturers such as Boehringer Ingelheim International GmbH, Zoetis Inc., etc., are engaging in mergers & acquisitions with small and medium regional players in the veterinary biologics market in order to streamline their product offerings in respective regions with diverse product portfolios.

More Valuable Insights on Veterinary Biologics Market

Future Market Insights brings a comprehensive research report on forecast revenue growth at global, regional, and country levels, and provides an analysis of the latest industry trends in each segment from 2014 to 2029. The global veterinary biologics market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the veterinary biologics market on the basis of product type (vaccines, monoclonal antibodies, bacterial extracts, immunomodulators, and allergenic extracts), animal type (companion animals, livestock, and equine), and distribution channel (veterinary clinics, veterinary hospitals, veterinary research institutes, and retail pharmacies), across seven major regions.

Request a Complete TOC of this Report with figures:
https://www.futuremarketinsights.com/toc/rep-gb-2288

Branded Generics Market is poised to expand at a CAGR of 5.8% over 2031

ESOMAR-certified consulting firm Future Market Insights (FMI) in its latest report forecasts that the global branded generics market will register healthy growth at a CAGR of 5.8% between 2021 and 2031.

The swift growth of branded generics market can be attributed to the growing number of patent expiry of branded or blockbuster drugs along with increasing prevalence of chronic diseases. Rising demand for cheap medical treatments is positively impacting the demand in the market.

Branded generics are pharmaceutical drugs that have been re-released with a different brand name. They are used to treat various diseases such as diabetes, hypertension, back pain and others. These drugs occupy small but lucrative subset of the entire generic market

Since branded generics are free from patenting, companies are investing handsome amounts on this drug category. The market is set to reach a valuation of around 283.2 Bn in 2021, with top players in tier-1 accounting for 20%-25% market share.

The entry of new players, simple market authorization procedures, greater profit margin and off-invoice discounts will expand branded generics market during the forecast period.

As per the FMI’s analysis, despite the slight setback due to the pandemic, the global branded generics market registered year-on-year (Y-o-Y) growth at 4.9% CAGR during 2020-2021.

Key Takeaways from FMI’s Branded Generics Market Study

China and India are spearheading the growth of Asia Pacific market spurred by the increasing adoption of branded generics by large-scale pharmacy chains in the emerging economies
The U.S. will lead the North America’s branded generics market, registering a growth at 3.83% CAGR during the forecast period.
The market in India is expected to offer lucrative growth opportunities to branded generics manufacturers backed the expansion of pharmaceutical industry

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1260

In terms of therapeutic application, cardiovascular diseases and diabetes are expected to account for considerable market share
Oral solid dose pharmaceutical formulation continues to be highly preferred among patients. The oral segment accounts for over 55% share of the global branded generics market.

Competitive Landscape

Teva, Abbott Laboratories, Novartis, Mylan, Pfizer are some prominent players operating in the branded generics market cumulatively hold around 20-25% market share.

Key players operating in branded generic market are focusing on expanding their business in emerging markets. They are adopting various organic and inorganic growth strategies such as mergers and acquisitions, advanced product development and collaborations to gain a competitive edge in the market.

In October 2020, Glenmark Pharmaceuticals, introduces NINDANIB (Nintedanib) for the treatment of pulmonary fibrosis in India. Glenmark has been amongst the first to launch the branded generic version at an affordable cost for the treatment of pulmonary fibrosis in India.

More Valuable Insights on Branded Generics Market

In its latest report, FMI provides an incisive coverage on the global branded generics market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031.The study provides compelling insights on branded generics market on the basis of therapeutic application (oncology, cardiovascular diseases, diabetes, neurology, gastro intestinal diseases, dermatology diseases, analgesic and others), drug class (alkylating agents, anti-metabolites, hormones, anti-hypertensives, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptics and others ), formulation type (oral, parenteral, topical, others) and distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, drug stores) across seven major regions.

For critical insights, request for PDF Brochure https://www.futuremarketinsights.com/reports/brochure/rep-gb-1260

Starch Recovery Systems Market 2022 Key Players, SWOT Analysis, Key Indicators, Forecast To 2029

The global starch recovery systems market size is expected to reach US$ 457 Mn by the end of 2029. According to the report, the growth of the market is driven by the demand for eco-efficient equipment for potato processing. The key drivers of the market are the growing potato processing industry and the R&D investments in processing operations. The report offers a comprehensive overview of the market, covering key growth drivers, restraints, opportunities, and prevailing trends. It uses unique research methods to offer the most accurate analysis of the market.

Starch is a carbohydrate derived from agricultural raw materials which are widely present in food applications. Market growth is fuelled by diversified applications of starch & its derivatives for food production and industrial purposes such as native starch, modified starch, maltodextrin, cyclodextrin and glucose syrup. In addition, it is one of the most important polymers used extensively daily in both food and non-food applications.

Commercialized goods such as corn and other types of cereals usually undergo physical modification or simple chemical modification to derive starch that can be used across various industries. Starch recovery systems therefore are likely to witness increasing demand in the coming years

Get | Download Sample Copy with Graphs & List of Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-11454

It includes in-depth insights into the starch recovery systems market. Some of these are:

The estimated value of the market was at US$ 265 Mn in 2019. Through the course of the report’s forecast period, the market is exhibited to show a steady pace of growth.
The hydrocyclones and centrifuges segment is estimated to lead the market with the largest share.
The rising demand for processed potato products has resulted in the growth of potato processing plants; this demand is driving the market for starch recovery systems.
APAC is projected to dominate the market during the forecast period.
The growing population, the increasing disposable income, and the rising demand for processed and convenience food products are expected to drive the market growth in APAC.
Some of the factors restraining the growth of the market include the stringent environmental & governmental regulations and the use of alternate technologies for starch recovery due to the high cost.
In terms of plant size, the small scale plants will hold dominance in the market through the course of the forecast period.

Despite High Demand, Change in Buying Decisions Due to COVID-19 Outbreak will Impact Growth

The starch recovery systems market does not yet seem to be benefiting from the situation happening over this pandemic. Market traders feel negatively disadvantaged now that many public markets have been closed. Growers who are missing out on sales are coming up with creative solutions, like drive-ins for the sale of their products. Also, more people than ever before in the starch recovery systems market are working from home. In general, businesses feel supported by the package of support measures that the government has announced. Rising population along with growing economic standards has led to increase in food service spending. However, contrary to aforementioned predictions, the market may be heading towards tough waters.

Who is Winning?

The key players in the market include GEA (Germany), Alfa Laval (Sweden), Andritz (Austria), NivobaHovex (Netherlands), MICROTEC ENGINEERING GROUP (Australia), Myande Group (China), Larsson Sweden (Sweden), Sino-Food Machinery (China), Flo-Mech (UK), and Hiller GmbH Germany). Large-scale potato manufacturers are preferring hydrocyclones and centrifuges to recover starch due to their multifunctionality. Potato processing up-gradation with eco-efficiency is encouraging the adoption of starch recovery systems, persuading the demand for hydrocyclones and centrifuges.

STARCH RECOVERY SYSTEMS MARKET TAXONOMY

The global Starch Recovery Systems market is segmented in detail to cover every aspect of the market and present complete market intelligence to readers.

Component

Refining sieves
Hydrocyclones and centrifuges
Vacuum filters
Screw conveyors
Filling stations

Plant size

Small
Medium
Large

Application

Frozen Products
Chips & Snack Pellets
Dehydrated Products
Filling stations

Region

North America
Latin America
Europe
South Asia
East Asia
Oceania
MEA

Buy This Report@ https://www.futuremarketinsights.com/checkout/11454

STARCH RECOVERY SYSTEMS MARKET – STRUCTURE ANALYSIS

Leading players are focusing on acquisitions and partnership to gain competitive advantage Besides this, they are focusing on the launch of novel technologies
In June 2018, Alfa Laval (Sweden) announced the launch of UniDisc, a new disk stack separator. This disk technology would increase the efficiency of separation by 30% due to the low spacing between the disks.
In September 2018, Ferrum (Switzerland) acquired Hiller GmbH (Germany). This acquisition would allow Hiller GmbH to improve its role in the economically competitive market and extend its operations in the regions of Asia and North America.

About FMI:

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Future Market Insights
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com

Non Thermal Pasteurization Market Emerging Trends, Size, Share and Growth Analysis by 2030

The global non-thermal pasteurization market size is expected to reach US$ 5.5 Bn by the end of 2030. According to the report, rising concern for food safety with growing demand for processed food containing active ingredients and consumer preferences for tastier and additive-free food is the major reason for boosting up the demand. The report offers a comprehensive overview of the market, covering key growth drivers, restraints, opportunities, and prevailing trends. It uses unique research methods to offer the most accurate analysis of the market.

Non-thermal pasteurization techniques such as high pressure processing, pulse electric field, ultrasonic and others have helped companies to meet the growing demand of consumers by increasing the production capacity and reducing the time required to process food. The adoption of non-thermal processes is increasing as they ensure inactivation of microorganisms, food preservation, freshness, and longer shelf life.

Get | Download Sample Copy with Graphs & List of Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-11441

It includes in-depth insights into the non-thermal pasteurization market. Some of these are:

The estimated value of the market was at US$ 1.1 Bn in 2020. Through the course of the report’s forecast period, the market is exhibited to show a steady pace of growth
North America region dominated the global non-thermal pasteurization market where as the Europe region held the second dominant position in the market
North America is dominates the non-thermal pasteurization market because of rising health consciousness among people related to food product
Europe has seen considerable growth as a result of increasing use of meat and beverage products in Spain, the U.K., and other nations, attracting numerous food companies to embrace non-thermal processing technology to manufacture safe and natural goods without added preservatives
Beverages segment to exhibit high demand

Lowered Production Due to COVID-19 Outbreak will Impact Growth

As demand decreases and the coronavirus spreads, supply-chain disruptions are making the companies suffer. The non-thermal pasteurization market is negatively affected by coronavirus due to the lockdown. Prices are declining due to less export activity. Lowered production and dwindling sales in non-thermal pasteurization companies are expected to have adverse impact on the overall market. With worsening business sentiment and the widespread shutdown of production sites in key markets, the  non-thermal pasteurization market is likely to experience a sharp decline in revenue.

Who is Winning?

Key players operating in the global non-thermal pasteurization market include Bosch, Emerson, Bühler, Hiperbaric España, Avure Technologies, Chic Freshertech, Elea Technology, Pulsemaster, Star, Dukane, Symbios Technologies, CHIC Foods Co. Ltd., Avure Technologies, Hormel Foods Corporation, Hain Celestial Group and American Pasteurization Company. In order to improve their market place on the global non-thermal pasteurization market, key players now concentrate on strategies such as product innovations, mergers & acquisitions, new technologies, joint ventures, collaborations and partnerships.

NON-THERMAL PASTEURIZATION MARKET TAXONOMY

The global Non-Thermal Pasteurization Systems market is segmented in detail to cover every aspect of the market and present complete market intelligence to readers.

Technique

High Pressure Processing (HPP)
Pulse Electric Field (PEF)
Microwave Volumetric Heating (MVH)
Ultrasonic
Irradiation

Form

Solid
Liquid

Application

Food and Beverages
- Dairy Products
- Ready Meals
Pharmaceuticals
Cosmetics

Region

North America
Latin America
Europe
South Asia
East Asia
Oceania
MEA

Buy This Report@ https://www.futuremarketinsights.com/checkout/11441

KEY RESEARCH FINDINGS

Non-thermal pasteurization is gaining popularity as a preferred technology for food processing for converting raw food items into products that are suitable for human consumption
Non-thermal pasteurization does not expose the food to high temperatures which helps to retain the taste, nutritional value of the food and appearance. The technology also helps to kill pathogens keeping the food safe
The increasing use of HPP in shellfish, sliced meat, vegetables, fruit, poultry, fish, juices & smoothies, ready-to-eat meals, sauces & salsas, and others is expected to drive the market
The non-thermal pasteurization food segment is expected to account for the largest share due to the growing use of HPP in meat products, fruits, cheese and ready-to-eat meals
High growth is expected in the North America non-thermal pasteurization market

About FMI:

Contact Us:

Future Market Insights
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com